Evidence map›Paper›PMID 36615860›Full record

ArticleNutrients2022

Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project.

Enric Sánchez, Marta Sánchez, Carolina López-Cano, Marcelino Bermúdez-López, José Manuel Valdivielso, Cristina Farràs-Sallés, Reinald Pamplona, Gerard Torres, Dídac Mauricio, Eva Castro and 2 more

Abstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Enric SánchezEndocrinology and Nutrition Department, University Hospital Arnau de Vilanova, Obesity, Diabetes and Metabolism (ODIM) Research Group, IRBLleida, University of Lleida, 25198 Lleida, Spain.ORCID 0000-0001-7345-1601
Marta SánchezEndocrinology and Nutrition Department, University Hospital Arnau de Vilanova, Obesity, Diabetes and Metabolism (ODIM) Research Group, IRBLleida, University of Lleida, 25198 Lleida, Spain.
Carolina López-CanoEndocrinology and Nutrition Department, University Hospital Arnau de Vilanova, Obesity, Diabetes and Metabolism (ODIM) Research Group, IRBLleida, University of Lleida, 25198 Lleida, Spain.ORCID 0000-0001-7458-5871
Marcelino Bermúdez-LópezVascular and Renal Translational Research Group, IRBLleida, Red de Investigación Renal, Instituto de Salud Carlos III (RedinRen-ISCIII), 25198 Lleida, Spain.
José Manuel ValdivielsoVascular and Renal Translational Research Group, IRBLleida, Red de Investigación Renal, Instituto de Salud Carlos III (RedinRen-ISCIII), 25198 Lleida, Spain.
Cristina Farràs-SallésCentre d'Atenció Primària Cappont, Gerència Territorial de Lleida, Institut Català de la Salut, Research Support Unit Lleida, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gorina (IDIAPJGol), 08007 Barcelona, Spain.
Reinald PamplonaDepartment of Experimental Medicine, IRBLleida, University of Lleida, 25003 Lleida, Spain.ORCID 0000-0003-4337-6107
Gerard TorresRespiratory Medicine Department, University Hospital Arnau de Vilanova and Santa María, Group of Translational Research in Respiratory Medicine, IRBLleida, University of Lleida, 25198 Lleida, Spain.
Dídac MauricioDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Sant Pau Biomedical Research Institute (IIB Sant Pau), 08025 Barcelona, Spain.ORCID 0000-0002-2868-0250
Eva CastroVascular and Renal Translational Research Group, IRBLleida, Red de Investigación Renal, Instituto de Salud Carlos III (RedinRen-ISCIII), 25198 Lleida, Spain.
Elvira FernándezVascular and Renal Translational Research Group, IRBLleida, Red de Investigación Renal, Instituto de Salud Carlos III (RedinRen-ISCIII), 25198 Lleida, Spain.
Albert LecubeEndocrinology and Nutrition Department, University Hospital Arnau de Vilanova, Obesity, Diabetes and Metabolism (ODIM) Research Group, IRBLleida, University of Lleida, 25198 Lleida, Spain.ORCID 0000-0001-9684-0183

Funding

Diputació de Lleida and Generalitat de Catalunya 2017SGR696 and SLT0021600250
6 · The paper itself

Abstract

There is controversial information about the accumulation of advanced glycation end-products (AGEs) in obesity. We assessed the impact of total and abdominal adiposity on AGE levels via a cross-sectional investigation with 4254 middle-aged subjects from the ILERVAS project. Skin autofluorescence (SAF), a non-invasive assessment of subcutaneous AGEs, was measured. Total adiposity indices (BMI and Clínica Universidad de Navarra-Body Adiposity Estimator (CUN-BAE)) and abdominal adiposity (waist circumference and body roundness index (BRI)) were assessed. Lean mass was estimated using the Hume index. The area under the receiver operating characteristic (ROC) curve was evaluated for each index. Different cardiovascular risk factors (smoking, prediabetes, hypertension and dyslipidemia) were evaluated. In the study population, 26.2% showed elevated SAF values. No differences in total body fat, visceral adiposity and lean body mass were detected between patients with normal and high SAF values. SAF levels showed a very slight but positive correlation with total body fat percentage (estimated by the CUN-BAE formula) and abdominal adiposity (estimated by the BRI). However, none of them had sufficient power to identify patients with high SAF levels (area under the ROC curve <0.52 in all cases). Finally, a progressive increase in SAF levels was observed in parallel with cardiovascular risk factors in the entire population and when patients with normal weight, overweight and obesity were evaluated separately. In conclusion, total obesity and visceral adiposity are not associated with a greater deposit of AGE. The elevation of AGE in obesity is related to the presence of cardiometabolic risk.

Indexed as

HypertensionObesityAdiposityBody Mass IndexCross-Sectional StudiesGlycation End Products, AdvancedHumansMiddle AgedObesity, AbdominalGlycation End Products, Advancedadipose tissueadvanced glycation end-productsbody compositioncardiometabolic riskcardiovascular risk factorsnovel targetsobesityskin autofluorescence

Identifiers

PMID36615860
PMCPMC9824455

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.